Spark Therapeutics, Inc. (ONCE): Barge Joseph La , officer of Spark Therapeutics, Inc. sold 3,000 shares on Jul 5, 2016. The Insider selling transaction was reported by the company on Jul 7, 2016 to the Securities and Exchange Commission. The shares were sold at $52.36 per share for a total value of $156,728.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 22, 2016, Hospital Of Philade Children’s (10% owner) sold 1,000,000 shares at $42.30 per share price.On Jun 16, 2016, Jeffrey D Marrazzo (Chief Executive Officer) sold 5,000 shares at $47.26 per share price.Also, On Jun 2, 2016, Anand Mehra (director) sold 500 shares at $60.00 per share price.On May 27, 2016, Katherine A High (director officer ) sold 10,000 shares at $54.00 per share price.
Shares of Spark Therapeutics Inc (ONCE) ended Tuesday, Jul 6, 2016 session in red amid volatile trading. The shares closed down -0.42 points or -0.79% at $52.58 with 3,49,119 shares getting traded. Post opening the session at $52.47, the shares hit an intraday low of $51.04 and an intraday high of $53.415 and the price vacillated in this range throughout the day. The company has a market cap of $1,441 M and the number of outstanding shares has been calculated to be 2,73,98,357 shares. The 52-week high of Spark Therapeutics Inc is $71.7499 and the 52-week low is $21.2.
Company has been under the radar of several Street Analysts.Spark Therapeutics Inc is Reiterated by Cantor Fitzgerald to Buy while Lowering the Price Target of the company shares to $ 94 from a previous price target of $100 . The Rating was issued on Jun 23, 2016.Spark Therapeutics Inc is Reiterated by SunTrust to Buy and the brokerage firm has raised the Price Target to $ 72 from a previous price target of $64 .The Rating was issued on Jun 21, 2016.Spark Therapeutics Inc is Initiated by Cantor Fitzgerald to Buy and the brokerage firm has set the Price Target at $100. The Rating was issued on Jun 3, 2016.Spark Therapeutics Inc is Initiated by Jefferies to Hold. The Rating was issued on Jun 2, 2016.
Spark Therapeutics Inc. (Spark) is engaged in developing products in the field of gene therapy. Spark’s product candidate SPK-RPE65 which is in Phase III clinical trial stage targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs) caused by non-sex linked or autosomal recessive mutations in the RPE65 gene. Spark is also developing various follow-on product candidates targeting other IRDs including SPK-CHM for the treatment of choroideremia (CHM). SPK-CHM is in Phase I/II dose-escalating clinical trial stage. The Company’s product development portfolio includes product candidates targeting expression of genes in the liver with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its SPK-FIX program for the treatment of hemophilia B. Spark also has preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases.